(DNLI) Denali Therapeutics - Ratings and Ratios
RIPK1 Inhibitor, LRRK2 Inhibitor, EIF2B Activator, TV Enzyme Replacement, Antibody TV
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 58.3% |
| Value at Risk 5%th | 87.7% |
| Relative Tail Risk | -8.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.13 |
| Alpha | -40.60 |
| CAGR/Max DD | -0.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.525 |
| Beta | 1.373 |
| Beta Downside | 1.378 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.20% |
| Mean DD | 34.78% |
| Median DD | 35.36% |
Description: DNLI Denali Therapeutics November 11, 2025
Denali Therapeutics Inc. (NASDAQ: DNLI) is a U.S.-based biopharmaceutical company that discovers and develops disease-modifying therapies for neurodegenerative disorders and lysosomal storage diseases.
Its pipeline spans several modality platforms: a RIPK1 inhibitor (Eclitasertib/SAR443122) for peripheral inflammatory conditions; an eIF2B activator (DNL343) targeting ALS; an LRRK2 inhibitor (BIIB122/DNL151) for Parkinson’s disease; a granulin-targeting antibody-drug conjugate (TAK-594/DNL593) for frontotemporal dementia; enzyme-replacement candidates for MPS III A (DNL126) and MPS II (Tividenofusp alfa/DNL310); and Transport Vehicle (TV) programs such as DNL952 for Pompe disease, DNL111 for Parkinson’s/Gaucher, and DNL622 for Hurler syndrome. The company also pursues OTV (oligonucleotide-transport vehicle) approaches against tau (DNL628) and α-synuclein (DNL422), plus an antibody-TV directed at Aβ (DNL921) for Alzheimer’s disease.
Recent data (Q3 2024) show DNLI holding approximately $1.2 billion in cash and marketable securities, with a cash-burn rate of roughly $150 million per quarter, reflecting heavy R&D spend (≈ $300 million YoY). The biotech sector is being driven by an aging global population, increasing prevalence of neurodegenerative disease, and a surge in venture capital funding that has lifted average biotech valuations by ~ 30 % year-over-year.
For a deeper, data-rich assessment of DNLI’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.39 (>2.0%) and ΔFCFTA -13.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 (>3.0%) and CFO -397.8m > Net Income -498.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (172.4m) change vs 12m ago 1.75% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 22.73%; Δ -22.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -18.96 (EBITDA TTM -513.7m / Interest Expense TTM -27.8m) >= 6 (WARN >= 3) |
Altman Z'' -19.41
| (A) 0.75 = (Total Current Assets 882.6m - Total Current Liabilities 90.1m) / Total Assets 1.06b |
| (B) -1.82 = Retained Earnings (Balance) -1.92b / Total Assets 1.06b |
| warn (B) unusual magnitude: -1.82 — check mapping/units |
| (C) -0.42 = EBIT TTM -526.4m / Avg Total Assets 1.25b |
| (D) -14.84 = Book Value of Equity -1.92b / Total Liabilities 129.4m |
| Total Rating: -19.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.98
| 1. Piotroski 0.0pt |
| 2. FCF Yield -20.83% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 |
| 5. Debt/Ebitda 0.09 |
| 6. ROIC - WACC (= -60.56)% |
| 7. RoE -46.33% |
| 8. Rev. Trend -57.19% |
| 9. EPS Trend -14.42% |
What is the price of DNLI shares?
Over the past week, the price has changed by +8.17%, over one month by +15.07%, over three months by +24.41% and over the past year by -22.12%.
Is DNLI a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DNLI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32 | 64.4% |
| Analysts Target Price | 32 | 64.4% |
| ValueRay Target Price | 18.7 | -4% |
DNLI Fundamental Data Overview November 26, 2025
P/S = 3643.6484
P/B = 2.8495
Beta = 1.134
Revenue TTM = 0.0 USD
EBIT TTM = -526.4m USD
EBITDA TTM = -513.7m USD
Long Term Debt = 44.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.16m USD (from shortTermDebt, last quarter)
Debt = 44.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -46.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.97b USD (2.78b + Debt 44.4m - CCE 848.2m)
Interest Coverage Ratio = -18.96 (Ebit TTM -526.4m / Interest Expense TTM -27.8m)
FCF Yield = -20.83% (FCF TTM -410.8m / Enterprise Value 1.97b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 105.0m) / Revenue TTM)
Tobins Q-Ratio = 1.87 (Enterprise Value 1.97b / Total Assets 1.06b)
Interest Expense / Debt = 47.48% (Interest Expense 21.1m / Debt 44.4m)
Taxrate = -0.02% (negative due to tax credits) (68.0k / -422.7m)
NOPAT = -526.5m (EBIT -526.4m * (1 - -0.02%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 9.79 (Total Current Assets 882.6m / Total Current Liabilities 90.1m)
Debt / Equity = 0.05 (Debt 44.4m / totalStockholderEquity, last quarter 926.2m)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -46.6m / EBITDA -513.7m)
Debt / FCF = 0.11 (negative FCF - burning cash) (Net Debt -46.6m / FCF TTM -410.8m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -47.25% (Net Income -498.7m / Total Assets 1.06b)
RoE = -46.33% (Net Income TTM -498.7m / Total Stockholder Equity 1.08b)
RoCE = -46.97% (EBIT -526.4m / Capital Employed (Equity 1.08b + L.T.Debt 44.4m))
RoIC = -48.92% (negative operating profit) (NOPAT -526.5m / Invested Capital 1.08b)
WACC = 11.64% (E(2.78b)/V(2.82b) * Re(11.07%) + D(44.4m)/V(2.82b) * Rd(47.48%) * (1-Tc(-0.00)))
Discount Rate = 11.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.68%
Fair Price DCF = unknown (Cash Flow -410.8m)
EPS Correlation: -14.42 | EPS CAGR: -12.10% | SUE: 0.07 | # QB: 0
Revenue Correlation: -57.19 | Revenue CAGR: -1.07% | SUE: -0.17 | # QB: 0
Additional Sources for DNLI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle